Background: Transplantation, surgical resection, radiofrequency ablation, and percutaneous ethanol injection are generally considered potentially curative treatments for patients with hepatocellular carcinoma (HCC). With the increasing incidence of HCC, it is critical to investigate geographic variations in curative treatments and their associations with survival among patients. Methods: A total of 6,782 patients with HCC during 2004 to 2011 were identified in the SEER-Medicare linked database and placed in quartiles based on the proportions undergoing potentially curative treatments per hospital referral region (HRR). Hierarchical Cox proportional hazards models were used to examine the association between regional potentially curative treatment patterns and survival across quartiles. Results: An average of 16.9% of patients with HCC underwent potentially curative treatments during 2004 to 2011, varying substantially from 0% to 34.5% across HRRs. Compared with patients residing in the lowest-quartile regions, those in the highest-quartile regions were more likely to be of other races (vs white or black), be infected with hepatitis B virus, and have more comorbidities. The 5-year survival was 4.7% in the lowest-quartile regions and 11.4% in the highest-quartile regions (P<.001). After controlling for confounders, patients in the highest-quartile regions had a lower risk of mortality (adjusted hazard ratio, 0.78; 95% CI, 0.72–0.85). Conclusions: Patients with HCC who resided in HRRs with higher proportions of potentially curative treatments had better survival. Given its proven survival benefits, prompt clinical and policy actions are needed to reduce variations in treatment utilization.
Submitted October 16, 2019; accepted for publication January 6, 2020.
Disclosures: Dr. Wang has disclosed that he receives grant/research support from Genentech. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: En Cheng, MD, MSPH, Department of Chronic Disease Epidemiology, School of Public Health, Yale University, 60 College Street, New Haven, CT 06510. Email firstname.lastname@example.org
NooneAM, HowladerN, KrapchoM, , eds. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed March 31, 2020.
WhiteDL, ThriftAP, KanwalF, . Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology2017;152:812–820.e5.
FongZV, TanabeKK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014;120:2824–2838.10.1002/cncr.28730)| false
El-SeragHB, SiegelAB, DavilaJA, . Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158–166.10.1016/j.jhep.2005.10.00216290309)| false
SonnendayCJ, DimickJB, SchulickRD, . Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636–1646.10.1007/s11605-007-0315-817912593)| false
AltekruseSF, HenleySJ, CucinelliJE, . Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542–553.10.1038/ajg.2014.1124513805)| false
WarrenJL, KlabundeCN, SchragD, . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8Suppl):IV-3–18.10.1097/00005650-200208001-00002)| false
HanazakiK, KajikawaS, ShimozawaN, . A 15-year retrospective study of hepatic resection for stage IV-A hepatocellular carcinoma shows value in hepatitis B negative patients. Am J Surg 2002;183:89–94.1186971110.1016/S0002-9610(01)00844-3)| false
PoonRT, FanST, NgIO, . Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003;237:376–383.10.1097/01.SLA.0000055224.68432.8012616122)| false
ChenVL, LeAK, KimNG, . Effects of cirrhosis on short-term and long-term survival of patients with hepatitis B-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2016;14:887–895.e1.2682040110.1016/j.cgh.2015.12.044)| false